$ONCO
Onconetix, Inc. Stock $onco

$onco Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000121390024073545 Filed on August 29, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$406.9K	$704.8K	$0.00
YoY Change
Cost Of Revenue	$301.4K	$604.1K
YoY Change
Gross Profit	$105.4K	$100.7K
YoY Change
Gross Profit Margin	25.91%	14.29%
Selling, General & Admin	$2.642M	$2.221M	$79.00K
YoY Change	-38.11%	2711.74%	-97.37%
% of Gross Profit	2506.23%	2205.48%
Research & Development	$109.4K	-$3.680K	$846.9K
YoY Change	-50.12%	-100.43%	-34.53%
% of Gross Profit	103.75%	-3.65%
Depreciation & Amortization		$201.3K	$0.00
YoY Change			-100.0%
% of Gross Profit		199.87%
Operating Expenses	$2.751M	$13.72M	$6.650M
YoY Change	-38.7%	106.26%	54.83%
Operating Profit	-$2.646M	-$13.62M	-$6.650M
YoY Change	-41.05%	104.75%	54.83%
Interest Expense		-$609.3K	$214.0K
YoY Change		-384.73%	606.26%
% of Operating Profit
Other Income/Expense, Net	-$1.238M	-$640.9K	-$215.7K
YoY Change	44.14%	197.17%	-103.13%
Pretax Income	-$3.884M	-$14.26M	-$6.870M
YoY Change	-27.41%	107.51%	61.09%
Income Tax	-$56.00K	$50.77K
% Of Pretax Income
Net Earnings	-$3.827M	-$14.31M	-$6.865M
YoY Change	-28.42%	108.39%	60.98%
Net Earnings / Revenue	-940.72%	-2029.76%
Basic Earnings Per Share	-$2.93	-$0.64	-$0.43
Diluted Earnings Per Share	-$2.93	-$0.64	-$0.21
COMMON SHARES
Basic Shares Outstanding	29.79M shares	22.33M shares	15.91M shares
Diluted Shares Outstanding	1.306M shares	22.20M shares	15.91M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$930.5K	$9.220M
YoY Change		-89.91%	-58.55%
Cash & Equivalents	$341.5K	$930.5K	$9.223M
Short-Term Investments
Other Short-Term Assets		$717.7K	$690.0K
YoY Change		4.01%	-44.88%
Inventory	$121.8K	$160.3K	$1.172M
Prepaid Expenses			$685.4K
Receivables	$98.03K	$171.3K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.048M	$2.035M	$11.41M
YoY Change	-89.02%	-82.15%	-51.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$69.32K	$69.19K	$14.12K
YoY Change	454.4%	390.01%	-20.58%
Goodwill	$38.86M	$36.50M
YoY Change
Intangibles	$21.41M	$20.31M	$17.91M
YoY Change	19.59%	13.43%
Long-Term Investments
YoY Change
Other Assets		$366.1K	$420.0K
YoY Change		-12.83%	313.55%
Total Long-Term Assets	$60.87M	$57.43M	$18.34M
YoY Change	231.89%	213.09%	15269.7%
TOTAL ASSETS
Total Short-Term Assets	$1.048M	$2.035M	$11.41M
Total Long-Term Assets	$60.87M	$57.43M	$18.34M
Total Assets	$61.92M	$59.46M	$29.75M
YoY Change	122.08%	99.9%	25.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.112M	$3.170M	$2.077M
YoY Change	29.47%	52.63%	113.44%
Accrued Expenses	$1.338M	$1.439M	$1.420M
YoY Change	-13.06%	1.34%	-31.75%
Deferred Revenue
YoY Change
Short-Term Debt		$14.99M	$8.620M
YoY Change		73.87%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$17.36M	$20.60M	$12.13M
YoY Change	-1.64%	69.8%	296.7%
LONG-TERM LIABILITIES
Long-Term Debt		$111.3K	$4.540M
YoY Change		-97.55%
Other Long-Term Liabilities		$435.9K
YoY Change
Total Long-Term Liabilities		$547.1K	$4.540M
YoY Change		-87.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.36M	$20.60M	$12.13M
Total Long-Term Liabilities		$547.1K	$4.540M
Total Liabilities	$20.90M	$23.96M	$16.67M
YoY Change	18.4%	43.7%	445.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$86.00M	-$82.21M	-$29.09M
YoY Change	149.74%	182.63%	136.65%
Common Stock	$83.00	$228.00	$169.00
YoY Change	-54.64%	34.91%	38.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$625.8K	$625.8K
YoY Change		0.0%
Treasury Stock Shares
Shareholders Equity	$33.91M	-$35.81M	$13.08M
YoY Change
Total Liabilities & Shareholders Equity	$61.92M	$59.46M	$29.75M
YoY Change	122.08%	99.9%	25.87%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$3.827M	-$14.31M	-$6.865M
YoY Change	-28.42%	108.39%	60.98%
Depreciation, Depletion And Amortization		$201.3K	$0.00
YoY Change			-100.0%
Cash From Operating Activities		-$3.200M	-$1.780M
YoY Change		79.75%	-44.07%
INVESTING ACTIVITIES
Capital Expenditures		$17.70K	$6.080M
YoY Change		-99.71%	-146959.9%
Acquisitions
YoY Change
Other Investing Activities			-$3.950M
YoY Change
Cash From Investing Activities		-$17.70K	-$10.04M
YoY Change		-99.82%	242412.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-343.4K	-210.0K
YoY Change		63.53%	-103.08%
NET CHANGE
Cash From Operating Activities		-3.200M	-1.780M
Cash From Investing Activities		-17.70K	-10.04M
Cash From Financing Activities		-343.4K	-210.0K
Net Change In Cash		-3.561M	-12.03M
YoY Change		-70.4%	-431.14%
FREE CASH FLOW
Cash From Operating Activities		-$3.200M	-$1.780M
Capital Expenditures		$17.70K	$6.080M
Free Cash Flow		-$3.217M	-$7.860M
YoY Change		-59.07%	147.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41294
	dei	Entity Registrant Name EntityRegistrantName	Onconetix, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-2262816
	dei	Entity Address Address Line1 EntityAddressAddressLine1	201 E. Fifth Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1900
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cincinnati
	dei	Entity Address State Or Province EntityAddressStateOrProvince	OH
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	45202
	dei	City Area Code CityAreaCode	(513)
	dei	Local Phone Number LocalPhoneNumber	620-4101
	dei	Security12b Title Security12bTitle	Common stock, $0.00001 par value
	dei	Trading Symbol TradingSymbol	ONCO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29790119	shares
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	930541	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4554335	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	171313	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	149731	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	160272	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	364052	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	773322	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	770153	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	2035448	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5838271	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	17423	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	69189	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	60654	usd
CY2024Q2	us-gaap	Deferred Costs DeferredCosts	366113	usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	366113	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	179983	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	148542	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20310890	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	25410887	usd
CY2024Q2	us-gaap	Goodwill Goodwill	36502332	usd
CY2023Q4	us-gaap	Goodwill Goodwill	55676142	usd
CY2024Q2	us-gaap	Assets Assets	59463955	usd
CY2023Q4	us-gaap	Assets Assets	87518032	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3169727	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5295114	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1438872	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2199867	usd
CY2024Q2	onco	Notes Payable Net Of Debt Discount NotesPayableNetOfDebtDiscount	89667	usd
CY2023Q4	onco	Notes Payable Net Of Debt Discount NotesPayableNetOfDebtDiscount	381627	usd
CY2024Q2	us-gaap	Notes Payable Current NotesPayableCurrent	10093425	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	9618373	usd
CY2024Q2	onco	Notes Payable Net Of Related Party NotesPayableNetOfRelatedParty	106180	usd
CY2023Q4	onco	Notes Payable Net Of Related Party NotesPayableNetOfRelatedParty	0	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	119474	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	74252	usd
CY2024Q2	onco	Subscription Agreement Liability Related Party Current SubscriptionAgreementLiabilityRelatedPartyCurrent	885600	usd
CY2024Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2641	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2641	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	20603559	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17190247	usd
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	111260	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	118857	usd
CY2023Q4	onco	Subscription Agreement Liability Related Party Non Current SubscriptionAgreementLiabilityRelatedPartyNonCurrent	864000	usd
CY2024Q2	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	375360	usd
CY2023Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	556296	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	60509	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	74290	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2805816	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3073781	usd
CY2024Q2	us-gaap	Liabilities Liabilities	23956504	usd
CY2023Q4	us-gaap	Liabilities Liabilities	21877471	usd
CY2024Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	64236085	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	64236085	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22848876	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22841975	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22331477	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22324576	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	228	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	228	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49405359	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49428809	usd
CY2024Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	517399	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	517399	shares
CY2024Q2	us-gaap	Treasury Stock Value TreasuryStockValue	625791	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	625791	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-82211470	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-56786194	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2378952	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2380920	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-35810626	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-5602028	usd
CY2024Q2	us-gaap	Minority Interest MinorityInterest	7081992	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	7006504	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-28728634	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1404476	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	59463955	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	87518032	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	704848	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1405281	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	604132	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1115565	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	100716	usd
	us-gaap	Gross Profit GrossProfit	289716	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2221275	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2302747	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5957725	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4068770	usd
CY2024Q2	onco	Research And Development ResearchAndDevelopment	-3680	usd
CY2023Q2	onco	Research And Development ResearchAndDevelopment	846853	usd
	onco	Research And Development ResearchAndDevelopment	45284	usd
	onco	Research And Development ResearchAndDevelopment	1929089	usd
CY2024Q2	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	1237140	usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	3530716	usd
CY2024Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	10261000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	15453000	usd
CY2023Q2	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	3500000	usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	3500000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	13715735	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	6649600	usd
	us-gaap	Operating Expenses OperatingExpenses	24986725	usd
	us-gaap	Operating Expenses OperatingExpenses	9497859	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13615019	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6649600	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24697009	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9497859	usd
CY2024Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	156169	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	380943	usd
CY2024Q2	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	205146	usd
CY2023Q2	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	213996	usd
	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	393429	usd
	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	213996	usd
CY2024Q2	onco	Fair Value Of Subscription Agreement Liability FairValueOfSubscriptionAgreementLiability	248000	usd
	onco	Fair Value Of Subscription Agreement Liability FairValueOfSubscriptionAgreementLiability	21600	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1674	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	59	usd
CY2024Q2	us-gaap	Other Income OtherIncome	-31602	usd
	us-gaap	Other Income OtherIncome	-3094	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-640917	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-215670	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-799066	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-214055	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14255936	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6865270	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25496075	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9711914	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	50768	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-70799	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-14306704	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6865270	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25425276	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9711914	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22196265	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15906725	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22171931	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15908560	shares
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-14306704	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6865270	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25425276	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9711914	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-110000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	4881144	usd
CY2024Q2	onco	Change In Pension Benefit Obligation ChangeInPensionBenefitObligation	-33406	usd
	onco	Change In Pension Benefit Obligation ChangeInPensionBenefitObligation	121272	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14230110	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6865270	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30185148	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9711914	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1404476	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	52650	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	4991144	usd
CY2024Q1	onco	Stock Issued During Period Value Of Changes In Pension Benefit Obligation StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation	154678	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-11118572	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-14497912	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	163	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	-775	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-110000	usd
CY2024Q2	onco	Stock Issued During Period Value Of Changes In Pension Benefit Obligation StockIssuedDuringPeriodValueOfChangesInPensionBenefitObligation	-33406	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-14306704	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-28728634	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	22388002	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	185578	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	33454	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2846644	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19693482	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	459	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	272781	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	25527	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6865270	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13075925	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25425276	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9711914	usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	3500000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	15453000	usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	3530716	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	291959	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	213996	usd
	onco	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty	293820	usd
	onco	Loss On Related Party Receivable LossOnRelatedPartyReceivable	165355	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	408001	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3269	usd
	onco	Fair Value Of Subscription Agreement Liability FairValueOfSubscriptionAgreementLiability	21600	usd
	us-gaap	Pension Expense PensionExpense	-24868	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	51875	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	458359	usd
	onco	Interest Accrued On Note Payable InterestAccruedOnNotePayable	95751	usd
	onco	Interest Accrued On Note Payable Related Party InterestAccruedOnNotePayableRelatedParty	87123	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	356637	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-59	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-70799	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	31501	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	159095	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	51900	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	220928	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	227201	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7749	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16882	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2188629	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	427409	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-893228	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-989319	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8431591	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6228769	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	79771	usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	6079771	usd
	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	3500000	usd
	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	454557	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22284	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3300	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22284	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10037628	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	5000000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	678550	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	400000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	417046	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	163	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	459	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	205093	usd
	onco	Payments For Purchase Of Treasury Shares PaymentsForPurchaseOfTreasuryShares	58981	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4861667	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-263615	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-31586	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3623794	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16530012	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4554335	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25752659	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	930541	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9222647	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	4405	usd
	us-gaap	Noncash Or Part Noncash Acquisition Inventory Acquired1 NoncashOrPartNoncashAcquisitionInventoryAcquired1	12947000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	150000	usd
	onco	Deferred Offering Costs Previously Prepaid DeferredOfferingCostsPreviouslyPrepaid	-11020	usd
	onco	Exerciseofprefundedwarrants Exerciseofprefundedwarrants	7	usd
	us-gaap	Stock Issued1 StockIssued1	5	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	87864	usd
CY2024Q2	us-gaap	Investments And Cash InvestmentsAndCash	900000	usd
CY2024Q2	us-gaap	Capital Units CapitalUnits	18600000	usd
CY2024Q2	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	-82200000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8400000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s condensed consolidated financial statements relate to accounting for acquisitions, valuation of inventory, the useful life of the amortizable intangible assets, estimates of future cash flows used to evaluate impairment of intangible assets, assumptions related to the pension benefit obligation, assumptions related to the related party subscription agreement liability, and accounting for income taxes. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span></p>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023Q4	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2024Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2641	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	888241	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2641	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	866641	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	700000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1400000	usd
CY2024Q2	us-gaap	Other Assets OtherAssets	56000	usd
	us-gaap	Accounts Receivable Sale AccountsReceivableSale	171000	usd
CY2023	us-gaap	Accounts Receivable Sale AccountsReceivableSale	150000	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	91971	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	139208	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	194805	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	68301	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	30039	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	160272	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	364052	usd
	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	400000	usd
CY2024Q2	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	400000	usd
CY2024Q2	us-gaap	Prepaid Insurance PrepaidInsurance	525848	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	122004	usd
CY2023Q4	us-gaap	Prepaid Rent PrepaidRent	312551	usd
CY2024Q2	onco	Prepaids Research And Development PrepaidsResearchAndDevelopment	74881	usd
CY2023Q4	onco	Prepaids Research And Development PrepaidsResearchAndDevelopment	89195	usd
CY2023Q4	onco	Prepaid Professional Fees PrepaidProfessionalFees	70708	usd
CY2024Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	55630	usd
CY2024Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	116963	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	175695	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	773322	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	770153	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	25447699	usd
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	3296644	usd
	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	1415884	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	20735171	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-36812	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	-397587	usd
	onco	Accumulated Amortization Foreign Currency Translation AccumulatedAmortizationForeignCurrencyTranslation	10118	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-424281	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	25410887	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20310890	usd
CY2024Q2	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P15Y
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	196000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	398000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	200000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	400590	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	801180	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	801180	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	801180	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	801180	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	7988107	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	11593417	usd
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P14Y5M19D
CY2024Q2	us-gaap	Indefinite Lived Trade Names IndefiniteLivedTradeNames	8700000	usd
CY2023Q4	us-gaap	Indefinite Lived Trade Names IndefiniteLivedTradeNames	9300000	usd
CY2024Q2	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	10300000	usd
	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	15500000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	55676142	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	15453000	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	3720810	usd
CY2024Q2	us-gaap	Goodwill Goodwill	36502332	usd
CY2024Q2	us-gaap	Compensated Absences Liability CompensatedAbsencesLiability	206722	usd
CY2023Q4	us-gaap	Compensated Absences Liability CompensatedAbsencesLiability	487579	usd
CY2024Q2	onco	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	378532	usd
CY2023Q4	onco	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	616707	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	212565	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	550415	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	358180	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	265849	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	93787	usd
CY2024Q2	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	100000	usd
CY2023Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	60530	usd
CY2024Q2	onco	Accrued Interest Related Party AccruedInterestRelatedParty	87123	usd
CY2024Q2	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	95750	usd
CY2023Q4	onco	Accrued Deferred Offering Costs AccruedDeferredOfferingCosts	125000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1438872	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2199867	usd
	onco	Royalty Sales Percentage RoyaltySalesPercentage	0.06	pure
CY2024Q2	onco	Sales Payments Amount SalesPaymentsAmount	22500000	usd
CY2024Q2	us-gaap	Noninterest Bearing Deposit Liabilities NoninterestBearingDepositLiabilities	5000000	usd
	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets	6000000	usd
	us-gaap	Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable	12947000	usd
	us-gaap	Asset Acquisition Consideration Transferred Transaction Cost AssetAcquisitionConsiderationTransferredTransactionCost	79771	usd
	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	19026771	usd
	onco	Inventory Fair Value InventoryFairValue	300000	usd
CY2024Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1200000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3500000	usd
CY2024Q2	us-gaap	Noncash Or Part Noncash Acquisition Inventory Acquired1 NoncashOrPartNoncashAcquisitionInventoryAcquired1	400000	usd
CY2023Q4	us-gaap	Asset Impairment Charges AssetImpairmentCharges	14700000	usd
CY2023Q4	us-gaap	Noncash Or Part Noncash Acquisition Inventory Acquired1 NoncashOrPartNoncashAcquisitionInventoryAcquired1	1200000	usd
CY2023Q4	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	1	pure
	us-gaap	Business Acquisition Pro Forma Information Description BusinessAcquisitionProFormaInformationDescription	(i) $3.5 million in cash at signing of the WraSer APA; (ii) $4.5 million in cash on the later of (x) 90 days after the signing of the WraSer APA or (y) the date that all closing conditions under the WraSer APA are met or otherwise waived (the “WraSer Closing Date”); (iii) 1.0 million shares of the Company’s common stock (the “Closing Shares”) issuable on the WraSer Closing Date, and (iv) $500,000 in cash one year from the WraSer Closing Date.
CY2023Q2	onco	Initial Payment Amount InitialPaymentAmount	3500000	usd
CY2023Q2	onco	Payments Payments	3500000	usd
CY2023Q2	us-gaap	Deposits Deposits	3500000	usd
CY2024Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	1100000	usd
CY2024Q2	us-gaap	Business Combination Separately Recognized Transactions Additional Disclosures Acquisition Costs BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts	500000	usd
CY2023Q4	onco	Voting Interest Percentage VotingInterestPercentage	1	pure
CY2023Q4	onco	Stock Issued During Period Shares Issuance Of Common Stock And Series B Preferred Stock In Connection With Pmx Transaction StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndSeriesBPreferredStockInConnectionWithPMXTransaction	3675414	shares
	onco	Business Acquisition Description Of Acquired BusinessAcquisitionDescriptionOfAcquired	i) the Company obtained 100% of the outstanding common stock and voting interest of PMX, (ii) at closing of the PMX Transaction, the PMX shareholders were issued approximately 17% of Onconetix’s outstanding common stock and none of the former PMX shareholders held more than 5% of Onconetix’s common stock individually, (iii) the composition of executive management and the governing body did not change sufficiently to give PMX or its former shareholders control over these functions within Onconetix, and (iv) Onconetix was significantly larger when considering both total assets and operations.
	onco	Royalty Rate RoyaltyRate	0.06	pure
CY2024Q2	us-gaap	Investment Owned At Cost InvestmentOwnedAtCost	1500000	usd
CY2023Q3	us-gaap	Long Term Debt Maturity Date LongTermDebtMaturityDate	2025-07-14
CY2024Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	100000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	400000	usd
CY2024Q2	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1100000	usd
CY2023Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1800000	usd
	onco	Milestone Payments MilestonePayments	2500000	usd
	onco	Milestone Payments Paid MilestonePaymentsPaid	500000	usd
	onco	Payable Average Discount Rate Percentage PayableAverageDiscountRatePercentage	0.082	pure
CY2023Q3	onco	Cash Payment To The Seller CashPaymentToTheSeller	1000000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	490000	usd
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5709935	shares
CY2024Q2	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	10000	usd
	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.15	pure
	onco	Percentage Of Net Proceeds PercentageOfNetProceeds	0.10	pure
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	90000	usd
CY2024Q2	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	100000	usd
CY2024Q2	us-gaap	Interest Expense Other InterestExpenseOther	200000	usd
	us-gaap	Interest Expense Other InterestExpenseOther	400000	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	100000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	100000	usd
	onco	Financing Fees FinancingFees	700000	usd
CY2024Q2	us-gaap	Investment Interest Rate Paid In Kind InvestmentInterestRatePaidInKind	0.0779	pure
CY2024Q2	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	300000	usd
	onco	Installment Payments installmentPayments	78000	usd
CY2023Q4	onco	Sale Of Units SaleOfUnits	20000000	shares
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.25
CY2024Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.25
CY2023	us-gaap	Product Liability Contingency Third Party Recovery Percentage ProductLiabilityContingencyThirdPartyRecoveryPercentage	0.55	pure
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Other Notes Payable OtherNotesPayable	3000000	usd
CY2024Q2	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	5709935	shares
CY2023Q4	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	2696729	shares
CY2024Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	269672900	shares
CY2023Q2	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	25032	shares
	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	57670	shares
CY2024Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	26000	usd
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	59000	usd
CY2023Q2	us-gaap	Accelerated Share Repurchases Final Price Paid Per Share AcceleratedShareRepurchasesFinalPricePaidPerShare	1.02
	us-gaap	Accelerated Share Repurchases Final Price Paid Per Share AcceleratedShareRepurchasesFinalPricePaidPerShare	1.02
CY2024Q2	srt	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	4500000	usd
CY2023Q1	onco	Fixed Commission Rate FixedCommissionRate	0.03	pure
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7899661	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.68
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	7899661	shares
CY2024Q2	us-gaap	Forward Contract Indexed To Equity Settlement Share Fair Value Per Share ForwardContractIndexedToEquitySettlementShareFairValuePerShare	0.167
CY2024Q2	onco	Warrants Issuable WarrantsIssuable	3000	usd
CY2023Q4	onco	Warrants Issuable WarrantsIssuable	3000	usd
CY2024Q2	us-gaap	Option Indexed To Issuers Equity Settlement Alternatives Shares At Fair Value OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue	447519	shares
CY2023Q4	us-gaap	Option Indexed To Issuers Equity Settlement Alternatives Shares At Fair Value OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue	447519	shares
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3150000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.08
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	83000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	167000	usd
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	207000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	479000	usd
CY2023Q2	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	150000	shares
CY2024Q1	onco	Restricted Shares Granted Vest Percentage RestrictedSharesGrantedVestPercentage	0.50	pure
CY2023Q2	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	25440	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	256580	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.03
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	3125	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.17
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	140955	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.98
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	12500	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	1.03
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	106250	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.03
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	12257	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.46
CY2024Q2	us-gaap	Shares Held In Employee Stock Option Plan Allocated SharesHeldInEmployeeStockOptionPlanAllocated	57812	shares
	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	3.15
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y9M14D
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	-775	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	272781	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	51875	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	458359	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	88000	usd
CY2024Q2	us-gaap	Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear	122000	usd
CY2022Q2	us-gaap	Short Term Lease Payments ShortTermLeasePayments	14000	usd
CY2024Q2	us-gaap	Payments For Rent PaymentsForRent	2000	usd
	us-gaap	Payments For Rent PaymentsForRent	51000	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	4000	usd
	onco	Percentage Of Subscription PercentageOfSubscription	0.02	pure
	onco	Aggregate Payments AggregatePayments	59750000	usd
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	209000	usd
CY2023	us-gaap	Dividends Paidinkind DividendsPaidinkind	159000	usd
CY2023	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	50000	usd
CY2024Q2	us-gaap	Other Receivables OtherReceivables	363000	usd
CY2024Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	usd
CY2023Q4	onco	Subscription Agreement Pmx Investor Percentage SubscriptionAgreementPMXInvestorPercentage	0.05	pure
CY2024Q2	us-gaap	Other Expenses OtherExpenses	10000	usd
	us-gaap	Other Expenses OtherExpenses	34000	usd
CY2024Q2	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	5000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	51000	usd
	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	71000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.12	pure
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1130026	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1419592	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	7899661	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	5264274	shares
	us-gaap	Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends	106250	shares
	us-gaap	Incremental Common Shares Attributable To Nonvested Shares With Forfeitable Dividends IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends	512940	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	5709935	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	14845872	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	7196806	shares
CY2024Q2	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.013	pure
CY2023Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0145	pure
CY2024Q2	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Weighted Average Interest Crediting Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate	0.013	pure
CY2023Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Weighted Average Interest Crediting Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate	0.0145	pure
CY2024Q2	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.033	pure
CY2023Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.03	pure
CY2024Q2	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	23794	usd
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	48444	usd
CY2024Q2	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	7293	usd
	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	14851	usd
CY2024Q2	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	-409	usd
	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	23086	usd
CY2024Q2	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-269	usd
	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	15177	usd
CY2024Q2	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	31765	usd
	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	-25032	usd
CY2024Q2	us-gaap	Pension Contributions PensionContributions	22000	usd
	us-gaap	Pension Contributions PensionContributions	43000	usd
CY2024Q2	us-gaap	Investment Interest Rate Paid In Cash InvestmentInterestRatePaidInCash	0.075	pure
	us-gaap	Management And Service Fees Rate ManagementAndServiceFeesRate	0.01	pure
	us-gaap	Legal Fees LegalFees	50000	usd
	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.1875
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.075	pure
	onco	Percentage Of Common Stock PercentageOfCommonStock	0.07	pure
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	onco	Subscription Agreement Liability Related Party Current SubscriptionAgreementLiabilityRelatedPartyCurrent		usd
CY2024Q2	onco	Subscription Agreement Liability Related Party Non Current SubscriptionAgreementLiabilityRelatedPartyNonCurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2024Q2	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges		usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges		usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt		usd
	us-gaap	Interest Expense Debt InterestExpenseDebt		usd
CY2023Q2	onco	Fair Value Of Subscription Agreement Liability FairValueOfSubscriptionAgreementLiability		usd
	onco	Fair Value Of Subscription Agreement Liability FairValueOfSubscriptionAgreementLiability		usd
CY2024Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023Q2	us-gaap	Other Income OtherIncome		usd
	us-gaap	Other Income OtherIncome		usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.61
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.15
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15906725	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15908560	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22171931	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22196265	shares
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax		usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax		usd
CY2023Q2	onco	Change In Pension Benefit Obligation ChangeInPensionBenefitObligation		usd
	onco	Change In Pension Benefit Obligation ChangeInPensionBenefitObligation		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2023Q1	onco	Stock Issued During Period Value Exercise Of Prefunded Warrants StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
	onco	Amortization Of Debt Discount Related Party AmortizationOfDebtDiscountRelatedParty		usd
	onco	Loss On Related Party Receivable LossOnRelatedPartyReceivable		usd
	onco	Fair Value Of Subscription Agreement Liability FairValueOfSubscriptionAgreementLiability		usd
	us-gaap	Pension Expense PensionExpense		usd
	onco	Interest Accrued On Note Payable InterestAccruedOnNotePayable		usd
	onco	Interest Accrued On Note Payable Related Party InterestAccruedOnNotePayableRelatedParty		usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment		usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets		usd
	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit		usd
	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	onco	Payments For Purchase Of Treasury Shares PaymentsForPurchaseOfTreasuryShares		usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	us-gaap	Noncash Or Part Noncash Acquisition Inventory Acquired1 NoncashOrPartNoncashAcquisitionInventoryAcquired1		usd
	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1		usd
	onco	Deferred Offering Costs Previously Prepaid DeferredOfferingCostsPreviouslyPrepaid		usd
	onco	Exerciseofprefundedwarrants Exerciseofprefundedwarrants		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess		usd
CY2024Q2	us-gaap	Prepaid Rent PrepaidRent		usd
CY2024Q2	onco	Prepaid Professional Fees PrepaidProfessionalFees		usd
CY2023Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent		usd
CY2024Q2	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent		usd
CY2023Q4	onco	Accrued Interest Related Party AccruedInterestRelatedParty		usd
CY2023Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest		usd
CY2024Q2	onco	Accrued Deferred Offering Costs AccruedDeferredOfferingCosts		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock		shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001782107

Files In Submission

Name	View Source	Status
0001213900-24-073545-index-headers.html	Edgar Link	pending
0001213900-24-073545-index.html	Edgar Link	pending
0001213900-24-073545.txt	Edgar Link	pending
0001213900-24-073545-xbrl.zip	Edgar Link	pending
ea0212631-10q_onconetix.htm	Edgar Link	pending
ea021263101ex31-1_onconetix.htm	Edgar Link	pending
ea021263101ex31-2_onconetix.htm	Edgar Link	pending
ea021263101ex32-1_onconetix.htm	Edgar Link	pending
ea021263101ex32-2_onconetix.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
onco-20240630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
onco-20240630_cal.xml	Edgar Link	unprocessable
onco-20240630_def.xml	Edgar Link	unprocessable
onco-20240630_lab.xml	Edgar Link	unprocessable
onco-20240630_pre.xml	Edgar Link	unprocessable
ea0212631-10q_onconetix_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ONCO
Onconetix, Inc. Stock $onco

2024 Q3 Form 10-Q Financial Statement

#000121390024073545 Filed on August 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONCO Onconetix, Inc. Stock $onco

2024 Q3 Form 10-Q Financial Statement

#000121390024073545 Filed on August 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONCO
Onconetix, Inc. Stock $onco